- Conditions
- Rheumatoid Arthritis
- Interventions
- Certolizumab Pegol + Methotrexate (MTX), Placebo + Methotrexate (MTX)
- Biological
- Lead sponsor
- UCB Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 359 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 70
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 63 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Observation of Ocrelizumab as Treatment in RRMS Patients
- Other
- Lead sponsor
- Wayne State University
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
- Interventions
- Pelabresib, Ruxolitinib, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 430 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Chandler, Arizona • La Jolla, California + 14 more
- Conditions
- Multiple Sclerosis
- Interventions
- High Efficacy Therapy (HET), Non High Efficacy Therapy (Non-HET)
- Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 4,361 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Sickle Cell Disease
- Interventions
- Mobile DOT
- Behavioral
- Lead sponsor
- Emory University
- Other
- Eligibility
- 2 Years to 65 Years
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 4
- States / cities
- Washington D.C., District of Columbia • Atlanta, Georgia • Chicago, Illinois + 1 more
- Conditions
- PSP - Progressive Supranuclear Palsy
- Interventions
- LM11A-31, Matching Placebo
- Drug
- Lead sponsor
- Adam Boxer
- Other
- Eligibility
- 41 Years to 86 Years
- Enrollment
- 147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Rheumatoid Arthritis
- Interventions
- sarilumab SAR153191 (REGN88), tocilizumab, hydroxychloroquine, methotrexate, sulfasalazine, leflunomide, subcutaneous placebo, intravenous placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 14
- States / cities
- Huntsville, Alabama • Colorado Springs, Colorado • Aventura, Florida + 10 more
- Conditions
- Arthritis, Rheumatoid
- Interventions
- Placebo, Sirukumab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,670 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 48
- States / cities
- Glendale, Arizona • Mesa, Arizona • Peoria, Arizona + 45 more
- Conditions
- Multiple Sclerosis
- Interventions
- Natalizumab 300 MG in 15 ML Injection
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Arthritis, Rheumatoid
- Interventions
- GSK3196165 (Otilimab), Sarilumab, Placebo to GSK3196165/ Sarilumab, csDMARDs
- Biological · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 550 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 46
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 36 more
- Conditions
- Relapsing Remitting Multiple Sclerosis
- Interventions
- Fingolimod, Disease Modifying therapy
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 881 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 122
- States / cities
- Cullman, Alabama • Phoenix, Arizona • Sun City, Arizona + 111 more
- Conditions
- Psoriatic Arthritis
- Interventions
- Ixekizumab, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 394 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 22
- States / cities
- Glendale, Arizona • Mesa, Arizona • Phoenix, Arizona + 19 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Vorso PROTECT System, Vorso PROTECT System - Sham (OFF)
- Device
- Lead sponsor
- Nesos Corp
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Duncansville, Pennsylvania
- Conditions
- Sickle Cell Disease
- Interventions
- Quality of Life measures
- Behavioral
- Lead sponsor
- Emory University
- Other
- Eligibility
- 3 Years to 23 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2014
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- Rheumatoid Arthritis
- Interventions
- Certolizumab Pegol, Placebo, Methotrexate
- Biological · Other
- Lead sponsor
- UCB Pharma SA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 880 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 70
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 63 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Abatacept, Adalimumab, Methotrexate
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 17 more
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- Ocrelizumab, Platform
- Drug
- Lead sponsor
- Georgia State University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- Rheumatoid Arthritis
- Interventions
- LY2127399, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,004 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 77
- States / cities
- Birmingham, Alabama • Paradise Valley, Arizona • Peoria, Arizona + 74 more
- Conditions
- Spinal Cord Injuries, Osteoporosis, Metabolic Syndrome
- Interventions
- Rosuvastatin Calcium, Placebo Oral Tablet, Coenzyme Q10, Calcium Carbonate, Vitamin D
- Drug · Dietary Supplement
- Lead sponsor
- Dr. B. Catharine. Craven
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Muscular Atrophy, Spinal
- Interventions
- Not listed
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- Not listed
- Enrollment
- 4,805 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Rheumatoid Arthritis
- Interventions
- Treatment Acceleration, Monthly Assessment
- Other
- Lead sponsor
- CorEvitas
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 538 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Albany, New York
- Conditions
- Hypercholesterolemia
- Interventions
- Alirocumab, Atorvastatin, Ezetimibe, Rosuvastatin, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 355 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 56
- States / cities
- Mobile, Alabama • Chandler, Arizona • Tucson, Arizona + 53 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Placebo for VIB4920, VIB4920 with TNFi, VIB4920 without TNFi
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 5
- States / cities
- San Francisco, California • Aurora, Colorado • Boston, Massachusetts + 2 more
- Conditions
- Multiple Sclerosis, Covid19
- Interventions
- Not listed
- Lead sponsor
- St. Barnabas Medical Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 45 participants
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Livingston, New Jersey